Submitted by Anonymous (not verified) on 18 October 2024 - 14:00
Safety and efficacy data requirements for applications for immunological VMPs intended for limited markets but not eligible for authorisation under Art 23 of Reg (EU) 2019-6 - Scientific guideline
Source: